Literature DB >> 19408003

[Intravitreal injections of medications in Germany. Contract situation and legal conditions].

F Ziemssen1, P Wiedemann, A Kampik, F Holz, K U Bartz-Schmidt.   

Abstract

Despite the increasing application of both approved and off-label drugs for intravitreal administration, the German health system still does not provide an accounting code for the procedure of intravitreal injections. Health insurances and politicians are exerting pressure in order to limit the expected increase in the number of medications and costs due to demographic factors. Although the price for the drug can be determined by the manufacturer, a standing committee has to agree on the fee to be charged for the medical service of injection and subsequent examinations. Until the missing arrangement has been made, each individual surgeon can balance accounts with the patients who have claim for reimbursement. Many contracts have recently been made in order to regulate the extent of performance and charges for the application of medications and follow-up examinations to reduce administration costs. Due to medical liability and ethical code, physicians are obliged to provide a cost-effective and adequate treatment as well as a comprehensive preoperative patient education including efficacy, potential complications, limited prescription and free choice of a medical practitioner. It also appears prudent to explain relevant terms such as 'off-label' and 'level of evidence'. To prevent any suspicion of personal advantage, patients should be informed if placed contracts do not allow equal reimbursement for the same treatment or similar drugs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19408003     DOI: 10.1007/s00347-009-1964-7

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  2 in total

1.  [New aspects in the therapy of neovascular age related macular degeneration. Current position of the Retinological Society, the Germany Ophthalmologic Society and the Professional Union of Eye Doctors of Germany].

Authors: 
Journal:  Ophthalmologe       Date:  2009-05       Impact factor: 1.059

2.  Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results.

Authors:  Peter K Kaiser; David M Brown; Kang Zhang; Henry L Hudson; Frank G Holz; Howard Shapiro; Susan Schneider; Nisha R Acharya
Journal:  Am J Ophthalmol       Date:  2007-10-22       Impact factor: 5.258

  2 in total
  5 in total

1.  Subjective evaluation of visual acuity is not reliable to detect disease activity in different exudative maculopathies.

Authors:  Marie-Christine Bruender; Nicola Benjamin; Hansjuergen Thomas Agostini; Andreas Stahl; Christoph Ehlken
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-06-01       Impact factor: 3.117

Review 2.  [Value and formats of quality assurance : Ophthalmology and intravitreal therapy between reality and wishful thinking].

Authors:  Nicole Eter; Daniel Pauleikhoff; Hansjürgen Agostini; Monika Fleckenstein; Focke Ziemssen
Journal:  Ophthalmologe       Date:  2020-04       Impact factor: 1.059

3.  [Visual self-assessment with the ACTO test during follow-up of AMD patients after intravitreal injections].

Authors:  A Cordes; A Strobel; C H Meyer; F Ender; N Schrage
Journal:  Ophthalmologe       Date:  2009-09       Impact factor: 1.059

Review 4.  [Legal aspects of quality assurance : Example of operative intravitreal injection therapy].

Authors:  Reinhold Preißler; Eva Hansmann; Klaus-Dieter Schnarr; Bernd Bertram; Focke Ziemssen
Journal:  Ophthalmologe       Date:  2020-04       Impact factor: 1.059

Review 5.  Endophthalmitis following intravitreal anti-vascular endothelial growth factor (VEGF) injection: a comprehensive review.

Authors:  Rohan Merani; Alex P Hunyor
Journal:  Int J Retina Vitreous       Date:  2015-07-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.